Business
Benny SatoOn assignment
Not verified yet. Benny Sato is reporting this story for the newsroom. Until then, this is gathered automatically from the outlets below.
Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
Benny Sato is reporting this story
What's new
- New headline Was: “Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump”
How it’s being reported
2 sourcesFirst reported by 
CNBC
CNBCFirstEli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Leads with what someone said.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump
Gives this outlet’s account of the story.